Podcasts about cme

What do you get when a top New York news anchor, a journalist, and a perimenopausal powerhouse writes a book? You get How to Menopause — a no-BS guide to midlife, straight from someone who lived it, confused, anxious, and totally unsupported. In this episode, I sit down with my friend and author Tamsen Fadal to talk about what it was like to unknowingly navigate perimenopause during a high-profile career, the moment she literally hit the bathroom floor, and why she turned her personal chaos into a mission to educate others. We talk hormones, misdiagnoses, pelvic floor surprises, brain fog on live TV, and why body composition matters now. Oh, and yes — she verbed “menopause.” This one's raw, real, funny, and totally relatable. Whether you're in the middle of it or still wondering what the hell is going on, this episode (and her book) is for you.

Feeling like your paycheck is your only safety net? It's time to change that. In this episode, Tracy Bingaman—PA, career coach, and your go-to brainstorming buddy—shares practical and creative ways to diversify your income as a clinician.From investing beyond retirement to medical surveys, teaching, consulting, and creative work like medical writing or coaching PA applicants, Tracy walks you through both active and passive income ideas that can help you build security and freedom.

Morgan started his career as a fitter turner and raised up through the rank to officer in theNavy. Morgan has over 30 years' experience in Lean and 25 years in Six Sigma, apragmatic and experienced improvement Leader, delivering over $2.21Bn in hard savings toorganization, improving customer, staff experiences and improved Health and Safety. Thelegacy capabilities of Business Improvement have resulted in over 23 international awards, 3literary awards and chairing 27 international conferences around Business Improvement andTransformation. Morgan has led an organization to be the first bank to a Shingo award andsupported a mining site in Chile to Shingo Prize. He is also a Chartered Engineer, CertifiedMaster Black Belt, Lean Master, and Executive Coach. Morgan has leadership experience inmarine, manufacturing, government, military, mining, utilities, telecommunications, oil andgas, banking, and supply chain.Regarded as a thought leader in behavioural transformation and a highly regarded coachwith challenging the status quo and developing new thinking.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Did you know that congenital heart defects (CHDs) affect nearly 40,000 babies born in the United States every year? On this episode, Pediatric Cardiologist Dr. Melissa Lefebvre and medical student Marina Hashim discuss the evaluation and management of common acyanotic congenital heart conditions. Specifically, they will: Review the classification of CHDs as cyanotic versus acyanotic. Discuss the pathophysiology of the three most common acyanotic CHDs – ASD, PDA, and VSD. Describe early clinical findings and use of diagnostic tools. Cover management options, ranging from spontaneous closure to surgical intervention. Explore prognosis and long-term outcomes on physical activity, neurodevelopment, and overall health. Special thanks to Dr. Rebecca Yang and Dr. Abeer Hamdy for peer reviewing this episode. CME available free with sign up: Link Coming Soon! References: Dimopoulos, K., Constantine, A., Clift, P., & Condliffe, R. (2023). Cardiovascular complications of down syndrome: Scoping review and expert consensus. Circulation, 147(5). https://doi.org/10.1161/CIRCULATIONAHA.122.059706   Dugdale, D. C. (Ed.). (n.d.). Pediatric heart surgery - discharge. Mount Sinai. Retrieved April 26, 2024, from https://www.mountsinai.org/health-library/discharge-instructions/pediatric-heart-surgery-discharge   Eckerström, F., Nyboe, C., Maagaard, M., Redington, A., & Hjortdal, V. (2023). Survival of patients with congenital ventricular septal defect. European Heart Journal,  44 (1,1), 54-61. https://doi.org/10.1093/eurheartj/ehac618   Heart MRI. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21961-heart-mri Leihao, S., Yajiao, L., Yunwu, Z., Yusha, T., Yucheng, C., & Lei, C. (2023). Heart-brain axis: Association of congenital heart abnormality and brain diseases. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1071820 Meyer, K. (Ed.). (2022, May 1). What is a ventricular septal defect (VSD)? Cincinnati Children's. Retrieved March 12, 2024, from https://www.cincinnatichildrens.org/health/v/vsd Minette, M. S., & Sahn, D. S. (2006). Ventricular septal defects. Circulation, 114(20). https://doi.org/10.1161/CIRCULATIONAHA.106.618124 Mussatto, K. A., Hoffmann, R. G., Hoffman, G. M., Tweddell, J. S., Bear, L., Cao, Y., & Brosig, C. (2014). Risk and prevalence of developmental delay in young children with congenital heart disease. Pediatrics, 133(3), e570–e577. https://doi.org/10.1542/peds.2013-2309 Pruthi, S. (Ed.). (2022, October 21). Ventricular septal defect (VSD). Mayo Clinic. Retrieved April 9, 2024, from https://www.mayoclinic.org/diseases-conditions/ventricular-septal-defect/symptoms-causes/syc-20353495     Right heart catheterization. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21045-right-heart-catheterization Shah, S., Mohanty, S., Karande, T., Maheshwari, S., Kulkarni, S., & Saxena, A. (2022). Guidelines for physical activity in children with heart disease. Annals of pediatric cardiology, 15(5-6), 467–488. https://doi.org/10.4103/apc.apc_73_22 Sigmon, E., Kellman, M., Susi, A., Nylund, C., & Oster, M. (2019). Congenital heart disease and Autism: A case-control study. Pediatrics, 144(5). https://doi.org/10.1542/peds.2018-4114 Thacker, D. (Ed.). (2022, January 1). Ventricular septal defect (VSD). Nemours Kids Health. Retrieved April 10, 2024, from https://kidshealth.org/en/parents/vsd.html   Tierney, S., & Seda, E. (2020). The benefit of exercise in children with congenital heart disease. Current Opinion in Pediatrics, 32(5), 626-632. https://doi.org/10.1097/MOP.0000000000000942  Ventricular septal defects (VSD). (2021, November 9). Cleveland Clinic. Retrieved April 2, 2024,from https://my.clevelandclinic.org/health/diseases/17615-ventricular-septal-defects-vsd    Ventricular septal defect surgery for children. (n.d.). Johns Hopkins Medicine. Retrieved April 11,2024, from https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/ventricular-septal-defect-surgery-for-children#:~:text=During%20this%20surgery%2C%20a%20surgeon,the%20hole%20between%20the%20ventricles Wernovsky, G., & Licht, D. J. (2016). Neurodevelopmental Outcomes in children with congenital heart disease - what can we impact?. Pediatric Critical Care Medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 17(8 Suppl 1), S232–S242. https://doi.org/10.1097/PCC.0000000000000800

“It wasn't a profession, it was a way of life,” observes internationally respected psychiatrist Dr. Nasser Loza, reflecting on a century-long family legacy in mental health care that began when his grandfather founded The Behman Hospital in Cairo. In this candid Raise the Line conversation with host Michael Carrese, Dr. Loza traces the transformation of psychiatry he's witnessed in his long career as increases in classifications, payment bureaucracy, reliance on pharmaceuticals, and technological disruption have each left their mark. The cumulative costs associated with these changes have, he laments, pushed care out of reach for many and hindered the human connection that is key to the discipline. He describes his prescription for countering these trends as a focus on effective and modest aims. “Rather than saying, come and see me in therapy for five years and I will make a better person out of you, I think focusing on symptom-targeted help is going to be what is needed.”  In this wide-ranging interview, you'll also learn about progress on advancing the rights of mental health patients and lowering stigmas, how to manage the rise of online therapy and use of AI chatbots, and the importance of empathy and transparency in mental health counseling. Don't miss this valuable perspective on a critically important dimension of healthcare that's informed by decades of experience as a clinician, government official and global advocate. Mentioned in this episode:The Behman HospitalMaadi Psychology Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Episode Summary In this special Tick Boot Camp Podcast episode, Dr. Myriah Hinchey (ND) joins Matt Sabatello and Rich Johannesen from Tick Boot Camp to spotlight the 2025 LymeBytes Symposium, a physician- and patient-focused conference designed to shorten the healing journey for Lyme, mold illness, PANS/PANDAS, Long COVID, and other complex, infection-driven chronic conditions. We dig into why immersive learning accelerates progress, how an intimate format fuels direct access to top clinicians and vendors, and what attendees—both in-person and virtual—will actually experience over two packed days in Fort Lauderdale. Exclusive Listener Offer: Use code TBC100 at checkout for $100 off in-person or virtual tickets at shop.lymebytes.com. Why This Episode Matters End the isolation: Dr. Hinchey explains how community, validation, and shared learning unlock momentum for both patients and clinicians. Immersion = speed: Concentrated exposure to leading experts and technologies helps you discover the next best step faster. Bridging the gap: Learn why precision care often requires a team—LLMDs, specialty labs, compounders, targeted supplements, and therapeutic devices—working together. What You'll Learn Inside the LymeBytes philosophy: Healthy, gluten- and dairy-free meals, beach-side community dinner, structured networking, and vendor access that mirror the lifestyle principles used in treatment. Adjunctive therapies on site: Demos and education around hyperbaric oxygen therapy (OxyHealth), infrared/red light, Relax Sauna, Therasage, plus niche supplement brands (e.g., Alight by Dr. Jill Crista, NutraMedix, Lymecore Botanicals) and specialty labs for Lyme, co-infections, and mold. Precision testing & interpretation: Why test results (e.g., Western Blots, specialty panels) must be read in clinical context, and how collaboration between vendors and clinicians personalizes care. PRP/TruDose spotlight: A primer on platelet-rich plasma (PRP) and how TruDose aims to reset immune function and calm the nervous system using your own platelets—plus a teaser for a future deep-dive episode. Virtual experience (no FOMO): Live access to all clinician lectures, slides, full-day recordings to rewatch/scrub, and new vendor mini-interviews so remote attendees don't miss the expo value. Who Should Attend the Symposium Patients & caregivers seeking credible, actionable strategies to shorten recovery time Clinicians (conventional, integrative, functional) looking to upgrade protocols for chronic infection and inflammation Allies & advocates ready to learn the truth about Lyme and related conditions from top voices in the field Anyone who wants direct access to vendors, labs, and tools that often stay off patients' radars Event Details (In-Person + Virtual) Dates: November 14–15, 2025 Location: Fort Lauderdale Marriott Pompano Beach Resort & Spa (Florida) Format: Limited-capacity, intimate event (≈180–200 attendees) fostering direct interaction with clinicians, researchers, and vendors Perks: Healthy meals (GF/DF), Friday night beach dinner, curated vendor hall, 14.5 CME credits available in person (additional fee) Virtual: Live stream + full-day recordings (Day 1 & Day 2), slide access, vendor mini-features Register: shop.lymebytes.com $100 Off: Use code TBC100 at checkout (in-person or virtual) Notable Quotes On immersion: “The more volume of opportunities in an immersive environment, the more your internal diagnostic system can sense what resonates—and that's often your next right step.” On community: “Patients and clinicians are often dismissed or isolated. This event builds real connections you can rely on after you go home.” On precision: “Chronic cases are outliers—they need specialized testing, targeted supplements, and coordinated care to get unstuck.” Call to Action If travel isn't possible, don't wait—join virtually to access the same lectures, slides, and full-day recordings. And if you can make it to Florida, come say hi to Rich and the Tick Boot Camp crew in person.

This episode is sponsored by Lightstone Direct LLC. Lightstone Direct LLC connects you to institutional-quality real estate investments backed by a $12-billion AUM firm that co-invests alongside you—your partner in building lasting wealth. All investments involve risk. Please visit LightstoneDirect.com for a full list of disclosures.__________________________________________________Can improv skills transform patient interactions in healthcare?Dr. Bradley Block and Tane Danger, share how improvisation fosters essential skills like active listening, empathy, collaboration, and adaptability. Drawing from over 20 years in improv theater, Tane explains techniques such as "Yes, And" to validate patient concerns and build trust, staying present to avoid jumping to conclusions, and using nonverbal cues for better rapport. Through fun exercises like one-word stories, Tane demonstrates how these tools help healthcare professionals slow down, connect authentically, and navigate unpredictable situations, ultimately making interactions more enjoyable and effective for both providers and patients.Three Actionable Takeaways:· Stay Present and Listen Actively: In healthcare, it's easy to jump to conclusions based on experience, but staying present ensures accurate diagnoses and builds patient trust. Repeat the last thing a patient says to start your response, slowing down your thought process, demonstrating engagement, and allowing their full story to unfold naturally for better outcomes. Embrace "Yes, And": Validate patient ideas by starting responses with "Yes" to affirm what they've said, then add "And" to build collaboratively, exploring their concerns without dismissal. This fosters open dialogue, rapport, and partnership, turning potential conflicts into constructive conversations that enhance understanding and adherence to treatment plans. Incorporate Theatricality: Use exaggerated nonverbal cues, like expressive facial reactions and body language, to show genuine interest in patients' stories. This "theatricality" amplifies empathy, making interactions more authentic and helping patients feel heard, even if you're familiar with their condition, ultimately strengthening trust and the therapeutic relationship. About the ShowSucceed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Tane Danger is an improviser with over 20 years of experience performing, teaching, and directing improv theater. He is the co-founder of Danger Boat Productions, which uses improv to facilitate important conversations and improve communication and collaboration. As artist-in-residence at the Mayo Clinic Lavin Center for Humanities in Medicine, he trains healthcare professionals in improv techniques to enhance connection, empathy, and quick thinking.  Website: tanedanger.comCompany Website: dangerboat.netAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of Bowel Sounds, hosts Dr. Peter Lu and Dr. Jenn Lee talk to Dr. Kevin Watson, pediatric gastroenterologist and Assistant Director of Clinical Informatics at Akron Children's Hospital and Associate Professor at Northeastern Ohio Medical University. We talk about the use of AI-powered ambient listening technology for clinical documentation and his experience introducing AI scribes to his hospital.Learning objectivesUnderstand the advantages and limitations of the current state of ambient listening technology for clinical documentation.Review practical guidance on usage of this technology in pediatric gastroenterology.Recognize key strategies for successful implementation and adoption of this technology.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

There is so much noise today when it comes to nutrition. How do we know which voices to listen to? How do we know what is truly evidence-based versus bogus fads? And most importantly, how do we address nutrition with patients?Do you know what to say when a patient asks you which diet is better - carnivore or paleo? How do you support a patient in their weight loss goals with appropriate language that encourages and educates, not demeans and defeats?My dear friend Colleen Sloan is back on the podcast today to answer all these questions and more. Colleen is a Registered Dietician turned Pediatric PA who recently launched the Obesity Medicine Nutrition Course. Her course is designed for clinicians and dieticians who treat obesity in patients of any age. The course is an all inclusive, comprehensive nutrition program that includes 13 self-paced modules taught by Colleen and 11 industry-leading experts. The course also includes a Resource Vault and online community. In addition to receiving a clear roadmap on how to successfully discuss and treat obesity, you also earn 10.5 CME credits!Tune into today's episode to learn more about the Obesity Medicine Nutrition Course as well as actionable tips you can use in clinic today when discussing obesity and nutrition with your patients. Obesity Medicine Nutrition Course (use code TRACY10 for 10% off): https://www.examroomnutrition.com/a/2148137603/dcrdFWdoSPONSORS

Keith Ferrazzi, is a #1 New York Times Bestselling Author of Never Eat Alone, Leading Without Authority, Competing in the New World of Work, and his newest book, Teamship: 10 Shifts to Becoming a Dream Team. Keith is recognized as the world's top executive team coach, having coached the transformation of Fortune 50 corporations, the World Bank, fast growth Unicorns and even governments of entire countries. You've perhaps seen him on the Today's Show, or CNN, or read his columns in Harvard Business Review, Forbes, WSJ, Fortune, Fast Company, and Inc. Magazine. Keith founded Ferrazzi Greenlight—a team coaching firm—and leads the greenlight research institute focused on team transformation. In addition to his mission of elevating human capital in the workplace, Keith is a passionate philanthropist and an advocate for transforming the foster care system.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

“Giving learners options gives them a better learning experience. It's more holistic and more comprehensive,” says Sean Moloney, CEO and founder of EmbodyXR, an extended reality platform focused on the use of immersive technologies in medical education. In this eye-opening Raise the Line conversation, Moloney explains how AI-powered extended reality (XR) --which integrates augmented, virtual, and simulation-based environments -- allows learners to interact with patients, explore multiple diagnostic choices, and experience varied outcomes based on their decisions. The result, he notes, is not only stronger engagement in learning, but a measurable improvement in understanding. Despite these gains, Moloney is quick to point out that he sees these technologies as complements to traditional training, not substitutes for it. “We'll never replace in-person teaching,” he says, “but we can make learners even better.” Beyond training future clinicians, the EmbodyXR platform is also offering new modes of patient and caregiver education, such as augmented reality guidance for using medical devices at home. Join host Lindsey Smith as she explores how EmbodyXR achieves and maintains clinical accuracy, the connectivity it offers between headsets, personal computers and mobile devices, and other capabilities that are shaping the future of how healthcare professionals and patients will learn. Mentioned in this episode:EmbodyXR If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dr. Thomas Gallagher joins host Dr. Amanda Redfern to share how to ethically and effectively disclose medical errors to patients. During the past 20 years, Dr. Gallagher's research has explored the intersection of healthcare quality, accountability, and communication. He has led a variety projects focused on the optimal response to adverse events and errors in healthcare, and developing systematic programs for preventing and responding to such events. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

How can curiosity help us to come together across lines of difference?How can we insist on finding commonality despite the current political environment?In this series on healthcare and social disparities, Dr. Jill Wener, a board-certified Internal Medicine specialist, anti-racism educator, meditation expert, and tapping practitioner, interviews experts and gives her own insights into multiple fields relating to social justice and anti-racism. In this episode, Jill provides a platform for Amara Lynch to interview her colleagues from Listening 4 Justice. They talk about the implications of a news story about a teacher in Idaho who had a sign on in her classroom that said, “Everyone is Welcome Here”, which led to significant controversy and protests in that community.Addie Lentzner is a youth activist, organizer, and student. Pat Prescott is a radio veteran who has hosted programs in New York and Los Angeles, America's top 2 radio markets. Folami Prescott-Adams, Ph.D. is the CEO of HTI Catalysts. Amara Lynch has degrees from Tufts and Bethel Universities and an ICF-accredited diversity coaching certification.LINKShttps://hticatalysts.net/listening-4-justice/**Our website www.consciousantiracism.comYou can learn more about Dr. Wener and her online meditation and tapping courses at www.jillwener.com, and you can learn more about her online social justice course, Conscious Anti Racism: Tools for Self-Discovery, Accountability, and Meaningful Change at https://theresttechnique.com/courses/conscious-anti-racism.If you're a healthcare worker looking for a CME-accredited course, check out Conscious Anti-Racism: Tools for Self-Discovery, Accountability, and Meaningful Change in Healthcare at www.theresttechnique.com/courses/conscious-anti-racism-healthcareJoin her Conscious Anti-Racism facebook group: www.facebook.com/groups/307196473283408Follow her on:Instagram at jillwenerMDLinkedIn at jillwenermd

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. Advances in genetic understanding and therapeutic development have led to an era of promising disease-modifying strategies. In this episode, Katie Grouse, MD FAAN, speaks with Renatta N. Knox, MD, PhD, author of the article “Facioscapulohumeral Muscular Dystrophy” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Knox is an assistant professor of neurology in the Division of Pediatric Neurology and Neuromuscular Section at Washington University School of Medicine in St. Louis, Missouri. Additional Resources Read the article: Facioscapulohumeral Muscular Dystrophy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Renatta Knox about her article on fascioscapulohumeral muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Welcome to the podcast, and please introduce yourself to our audience. Dr Knox: Hi Katie, thank you so much for the invitation for the audio interview. I'm looking forward to our conversation. As she mentioned, my name is Renata Knox. It's a pleasure to be here today. Dr Grouse: I'd like to start by asking, what is the key message that you hope your readers will take from your article? Dr Knox: I would say two things. The first is an appreciation and understanding of the unique genetic mechanism that leads to FSHD. And the second is the really exciting therapy landscape that we find ourselves in. So, we're hopeful that there will actually be disease-modifying therapies for FSHD soon. Dr Grouse: We're really looking forward to learning more about that. Now, before we get to that piece, could you just remind us of the clinical manifestations and features that are specific to FSHD? Dr Knox: So, one of the most unique things about FSHD that we see clinically is the pattern of weakness. So, one of the first features is that it's asymmetric. And then there are certain muscle groups that typically are affected, and that's partly where the name comes from. So, we see effects in the face, the limbs, the trunk; and so, those are some of the unique features that we see clinically. Dr Grouse: I'd love it if you could walk us through how you approach diagnosing a patient who presents with proximal weakness where FSHD is in your differential. Dr Knox: Yeah, it's a really great question. So, I would say it depends. So, I actually focus on FSHD in my clinical practice. So, many times patients are referred to me because there's a very high suspicion or there's a known family history of FSHD. So, that's one category of cases. I would say the other category of case is where it's, as you said, maybe more proximal weakness more broadly. Someone that's before me who has a known family history, they really have some of the characteristic physical features---which I'm pretty attuned to, as this is, you know, part of my subspecialty---I'll actually go directly to FSHD genetic testing. And that is one of the unique features of this disease, that the next-generation sequencing panels that are typically used for some of our other muscle diseases, FSHD is not captured on those. So, we actually have to send targeted testing for FSHD to diagnose it. So, that is one category where, again, I have a very high suspicion either based on their clinical presentation and/or a known family history, then I will actually go directly to FSHD-targeted genetic testing. In the second case, where it is one of the conditions that I'm considering among others, I will do more broad testing. So, I will get a CK level to see if there's evidence of muscle breakdown. I'll likely also do one of the next-generation sequencing panels that we have access to, which will allow us to identify, potentially, one to two hundred potential muscle diseases. And then again, if FSHD is higher on my differential in that second group of patients, then I will also send targeted FSHD-specific testing. Dr Grouse: That's really helpful. And I'm wondering if you have any thoughts about common pitfalls that you've seen when providers are trying to work this up? Dr Knox: I don't know if I would say pitfalls. I think I would acknowledge that it's challenging. My subspecialty training in neuromuscular medicine and also gene therapy. And so FSHD is pretty high on my radar. But I would say in neurology in general---and then, you know, the general medical population---,it really isn't something that many people are seeing. So, I would say what patients will communicate to us sometimes is some frustration that maybe it took time to make the diagnosis, but I just have a deep understanding that it's not something that is on many people's radars. And I think, again, it's tricky because it's not picked up on these next-generation sequencing panels, which many of us can send pretty easily. It will be missed. And I will say the biggest pitfall is, again, if you're not thinking about it and you don't send that testing, you actually- it's very difficult to diagnose it. Dr Grouse: Thank you so much for highlighting that. I think there are many people who are not aware that those different panels really aren't picking that up and that they have to test specifically. So, I think that's a great thing for all of us to keep in mind. Are there any tips or tricks to the diagnosis, other than the genetic issues that you mentioned, that sometimes can really bring this diagnosis to the forefront? Dr Knox: I think things that really tip me off to having a higher suspicion for FSHD is facial weakness that we can detect on our exam. Scapular winging---again, there's a small subset of disorders which can impact that. Someone who's presenting with foot drop, you know, with facial weakness, I think definitely about FSHD more. Also, clinically, kind of the presentation or things that they're beginning to have difficulty with is a tip-off. So, if someone is an athlete, like, they're a volleyball player or basketball player and they say, oh, I'm having difficulties, you know, with movements that require them to elevate their arm, which can be a sign of the shoulder weakness that we classically see. Or someone who says, oh, I'm having a harder time shampooing my hair or combing my hair. So those can be tip-offs again, which are basically referencing the type of weakness that they have. Another feature of FSHD which isn't necessarily as broadly appreciated is that pain and fatigue are very common. So, if someone is coming in and saying, actually, I also have a significant amount of fatigue as well or a lot of pain, that's something that can tip me off to it. Hearing loss is something that we can also see in up to 20% of patients with FSHD. So, if they are having those symptoms or saying they're ringing in their ears, these are some things that will make me begin to think about it more. Dr Grouse: Oh, really helpful. I also found it really fascinating reading some of the very FSHD-specific clinical signs, some interesting- some diagrams and pictures as well, that are very specific to the pattern of weakness that develops in FSHD. So, I encourage our listeners to check that out. But are there any highlights from those little clinical pearls that you'd like to point out? Dr Knox: I think the poly-hill sign---so, these are these literal hills that we can see in the shoulders of patients with FSHD---is pretty classic. Popeye arms, which is this older term that we still use that has to do with which muscle groups are preserved versus those that have atrophy. So that's a common feature. And then I would say, really, the asymmetry is something that is a unique feature in FSHD. And again, we did our best to provide good representative images. So again, as you mentioned, Katie, I would really encourage people to look at those images and then think about cases that they may have seen and how similar they are so they can begin to recognize those signs as well. Dr Grouse: Now going back to the genetic topic, the complex genetic underpinnings of FSHD are really well-explained in your article; and again, worth taking a look at to remind ourselves of everything that's of that pathology. Now, I was wondering though, if you could give us a brief overview of how we should approach genetic testing in a suspected case of FSHD? You mentioned some specific panels, but it does sound like there's some more complexity to it as well. Dr Knox: Yes, and I'll just kind of briefly explain that complexity. Part of the thing that we're detecting in the genetic testing is the repeat number. And so, we're actually looking for a contraction in a repeat number. So, not an expansion, which were typical for some of the diseases that we think about, the trinucleotide repeat disorders. And this is why it's not captured in the next-generation sequencing panels, because they do not currently have the ability to do that. And so, again, what the type of testing that I do really depends on my suspicion. So again, if my suspicion is very high for FSHD---they have a family history, they have the classic features---then I will actually go directly to an FSHD-specific testing, which is available from various sources. If, again, it's among different things that I'm thinking about, I will get a CK lab. I typically will also send a next-generation sequencing panel specific for muscle diseases, perhaps muscular dystrophy; again, depending on what I'm thinking about. And then I will also send in a specific FSHD genetic test as well. People are beginning to use whole-genome sequencing, which is capturing some of our true nucleotide repeat disorders and becoming more comprehensive. So, my hope is that as that becomes more standard of care---like, whole-exome sequencing can be gotten pretty routinely now---that it may be easier for us to make some of these diagnoses. Dr Grouse: Well, that's really helpful, and thanks for that overview. Now another thing that you mentioned that I thought was really interesting in your article was that patients with, you know, history of FSHD, perhaps in the family, who are pregnant and want to screen for this disease would not be able to use sort of the more common screening tests like cell-free DNA testing and may have to go to other means to do that. What is generally their route to this type of testing? Dr Knox: Yeah, great question, and really important question for family planning purposes, and it definitely comes up in clinical practice. And so again, because of the unique genetics of FSHD, you actually have to do invasive genetic testing currently to be able to test it. And so that's, you know, amnio or chorio, and then send it to a lab that can perform, again, FSHD-specific testing on the samples that are presented. And there are obviously labs that are capable of doing that and centers that are capable of doing that, but it is not picked up on the cell-free DNA panels that are being very routinely used. You or your provider has to be thinking about it to send that specific testing, similar to our patients that come into clinic and have not yet been diagnosed. Dr Grouse: Once you have the diagnosis, what are our options for therapy? I think it sounds like at this current time, it looks to be mostly supportive. What are some of the supportive care options we should keep in mind? Dr Knox: Yes, so that is definitely accurate. Care today is supportive, but again, we're very excited about the clinical trial and therapy landscape for FSHD. So, I work very closely with my physical therapy colleagues that are in clinic with me. So, we work very closely with physical and occupational therapists to help with supportive measures, adaptive measures, doing assessments, helping our patients to be able to move and exercise safely and effectively. As I mentioned, pain is very common in FSHD and so we can treat that with medications. The most common medication that we use to treat for pain in FSHD are NSAIDs. And then other than that it's really, you know, supportive measures. Do they need to see other subspecialists? There are some surgical options. Those are used very rarely to help with some of the scapular weakness, but typically it's physical therapy, occupational therapy, supportive devices. We treat the pain as we're able to, and then we work with other subspecialists to screen, monitor and support our patients to the best of our ability. Dr Grouse: Well, without further ado, I'd love to hear more about what's coming down the pipeline in clinical trials. What can we look forward to seeing, hopefully, in future years to treat these patients? Dr Knox: Yes. And so, this is actually what got me interested in the neuromuscle space in general is that, because we now for many years have known the genetic cause of many of these disorders as well as some of the underlying mechanisms, we can actually use advances in therapeutics to do what we call targeted therapies. So, rather than treating symptoms or indirect methods or doing kind of broad drug screens---which, again, still do take place and still do have their place---we actually can target mechanisms directly. And so, we know that the underlying biology of FSHD is due to this protein called DUX4 being expressed when it should not be. So, it's what we call a toxic gain of function. And so, the targeted way to address this is to suppress DUX4 expression. And so, kind of broadly speaking, what we're really excited about are a couple of products that are currently in clinical trials right now that actually caused DUX4 suppression to be suppressed. And again, these are targeted pathways. And so, again, the hope is that by doing that, we can hopefully slow the progression of the disease, potentially stop progression of the disease, and potentially reverse. Again, we don't know if that might be possible, but that is one of the hopes. Dr Grouse: Well, that's really exciting, and I know we're all looking forward to more coming down the pipeline soon, and hopefully more things that can really offer some exciting treatments for our patients with this condition. Now, a little more deep-dive into our patients who are diagnosed. You've reviewed some of the treatments currently available and hopefully may someday soon be available. Are there other things that we should be keeping in mind in this population? For instance, screenings that we should be doing for other extramuscular manifestations that we need to be thinking about? Dr Knox: I will answer that question two ways. I think something that's very important to acknowledge is the impact that these diagnoses and these conditions have on our patient practically, psychologically. One of the other unique features of FSHD is, it's autosomal-dominant. So, if it is in a family, you can have many family members who are affected, but the variability is very high. And so, you can have in the same family someone who is wheelchair-dependent, and someone else in the family with the same underlying genetics who has no signs or symptoms or is very mildly affected. And that is something that is definitely challenging for our families and patients to navigate if they're very different than their family members with the same condition. And just navigating the world with a condition that, you know, can be physically debilitating and cause changes to what they're able to do or not able to do, progression is something that's very difficult to handle. So, I think that's one set of things. And we try our best, you know, with my team and my other colleagues in the space, to support our families and patients in the best way that we can. Secondly, there is very important screening that needs to be done for this condition. So, one of the things- and the current guidelines which are actually being updated, the last update was in 2015 is all patients that undergo pulmonary function testing or PFTs. And so that's something we do at baseline and we do at least annually in my practice. Young kids who are presenting very early or patients with certain genetics that we know are more predisposed to extra muscular manifestations, we recommend screening for hearing, which is one of the manifestations, and ophthalmologic exam to look for retinovascular changes, which is one of the manifestations as well. Those are the more common ones that are typically done. There's also some evidence in pediatric patients with very severe manifestations that there may be some cognitive impacts, learning impacts. And so, that is something we're also thinking about screening and supporting our patients in that way. And again, we typically work with these patients in a multidisciplinary team depending on what manifestations and the degrees to which they're impacted by the disorder. Dr Grouse: Thank you so much for that answer. I think a lot of us forget sometimes when we get really focused on what can we do now, that we forget to kind of stop and reflect on sort of the more holistic approach. How is this affecting the patient? How is this affecting the patient's family dynamic, and what other ways are they going through life with this condition that we need to be thinking about? So, I appreciate you bringing that up. I wanted to ask, sort of based on what you're talking about and what you mentioned already, you happened to mention that what initially drew you that to this work was your interest in some of the really exciting breakthroughs in the field. Well, was there anything else that drew you to, specifically, congenital neuromuscular diseases, and FSHD in particular? Dr Knox: I'm a physician scientist by training, and so I would describe myself also as a molecular biologist. So, I love getting into the nitty gritties of disease mechanisms, what genes are doing in bodies, how they function. And so, as I mentioned earlier, in the neuromuscle space, we've known for many years the genetic cause of many of these disorders and have done great, you know, mechanistic work to kind of define why we see the disease. And then now we're at this intersection of that knowledge marrying with these really novel therapeutic approaches, gene therapy approaches, being able to intersect and then in very creative ways actually target diseases very directly. And so, I would say it really is the combination of those two things. FSHD has a really fascinating unique biology, which again, we encourage everyone to read about more in the article. That really drew me to it. I'm very interested in gene regulation, transcription. This is one of the underlying mechanisms that is gone awry in the disorder, and then that being married to advances in therapeutics. So, you could wed those two pieces of information and actually meaningfully impact patient 's lives. And again, that's the real privilege and honor to witness is how these therapies can transform lives. And I saw it happened with this one case for this one disorder when I was a resident where there was no treatment. Young children, unfortunately, would not survive the disease. And then I saw the therapy come be in development and literally change the trajectory. And this is what we're very hopeful for in the FSHD space, that wedding, this wonderful basic science research, translational research, companies working together to develop these therapies that can transform lives. It is just so beautiful to witness and see, and it's something that I get to do. You know, it's a part of my job, so it's a real privilege. Dr Grouse: Well, I have to say, it's really inspiring hearing you talk about it. And I imagine that many neurologists-in-training who are listening to this may be inspired as well and may be convinced to go into this field for that very reason. So, thank you so much for sharing all of this information with us today. I learned a lot, and I think all of our listeners have too. Dr Knox: Thank you. It's really been a pleasure. Dr Grouse: Again, today I've been interviewing Dr Renatta Knox about her article on fascioscapulohumeral muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Pediatrician Dr. Paul Bunch consults Dr. Kahleb Graham from the Division of Gastroenterology, Hepatology, and Nutrition and Dr. Megan Miller from the Division of Behavioral Medicine and Clinical Psychology on disorders of gut-brain interaction. Episode recorded on September 17, 2025.    Resources discussed in this episode: Anxiety Assessment - Community Practice Support Tool Anxiety Management - Community Practice Support Tool Chronic Nausea and Vomiting - Community Practice Support Tool  Functional Abdominal Pain - Community Practice Support Tool     Financial Disclosure:  The following relevant financial relationships have been disclosed: None All relevant financial relationships listed have been mitigated. Remaining persons in control of content have no relevant financial relationships. To Claim Credit: Click "Launch Activity." Click "Launch Website" to access and listen to the podcast. After listening to the entire podcast, click "Post Test" and complete.   Accreditation In support of improving patient care, Cincinnati Children's Hospital Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Specific accreditation information will be provided for each activity. Physician:  Cincinnati Children's designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Nursing:  This activity is approved for a maximum 0.75 continuing nursing education (CNE) contact hours. ABP MOCpt2: Completion of this CME activity, which includes learner assessment and feedback, enables the learner to earn up to 0.75 points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. Cincinnati Children's submits MOC/CC credit for board diplomates.   Credits AMA PRA Category 1 Credits™ (0.75 hours), ABP MOC Part 2 (0.75 hours), CME - Non-Physician (Attendance) (0.75 hours), Nursing CE (0.75 hours)  

Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence.

This episode is sponsored by Lightstone Direct LLC. Lightstone Direct LLC connects you to institutional-quality real estate investments backed by a $12-billion AUM firm that co-invests alongside you—your partner in building lasting wealth. All investments involve risk. Please visit LightstoneDirect.com for a full list of disclosures.__________________________________________________What happens when money, meant as a tool, becomes the driving force of our lives, sidelining health, family, and purpose?In this transformative episode of Succeeded Medicine Podcast, Carl Richards, joins Dr. Cobin Soelberg to unpack how society—especially in the U.S.—has "lost the plot" on money. Drawing from his four years in New Zealand, where he noticed a cultural shift prioritizing life over work, Carl challenges the Western tendency to make money and work the organizing principles of existence, often at the expense of sleep, health, and relationships. He shares a vivid metaphor of money as a discouraged golden retriever, earnestly trying but failing to deliver intangibles like love, happiness, or self-worth. For physicians, this resonates deeply with the pressures of high-stakes careers and financial expectations. Carl offers actionable insights: assign money specific "jobs" it can handle (e.g., funding experiences or security) while releasing it from impossible tasks (e.g., defining self-esteem). He introduces the concept of "forcing functions"—deliberate commitments like signing up for a retreat or coaching a child's soccer team—to align actions with values. Reflecting on his retreats, including a women's financial advisor event and an upcoming couples' retreat, Carl emphasizes creating safe spaces for tough conversations about risk, uncertainty, and values. He advocates for quiet reflection—whether through meditation, gardening, or mountain biking—to escape the "matrix" of comparison and competition, a trap many physicians face in demanding healthcare systems. Three Actionable Takeaways: Reframe Money as a Tool to Serve Your Values: Physicians often face societal pressure to prioritize financial success, but Carl emphasizes that money is a tool, not the goal. It excels at funding tangible needs like a secure retirement or family vacations but fails at delivering intangibles like love, self-worth, or happiness. To apply this, list your core values (e.g., family time, patient care, personal health), then evaluate your financial decisions—such as investments or practice expenses—to ensure they align with those values, reducing stress and fostering purpose.Use Forcing Functions to Drive Intentional Change: Carl's concept of "forcing functions" involves committing to actions that push you toward your desired life, even if uncomfortable. For physicians, this might mean signing up to coach your child's soccer team to prioritize family, enrolling in a mindfulness retreat to combat burnout, or scheduling regular "quiet time" to reflect on career goals.Prioritize Quiet Reflection to Escape the Comparison Trap: The healthcare system's competitive "matrix" can erode well-being, but Carl advocates for intentional pauses—through meditation, nature, or activities like mountain biking—to rediscover what truly matters. Physicians can carve out 10-20 minutes daily for journaling or mindfulness to clarify their "world," as inspired by David Whyte's Sweet Darkness. This practice counters burnout by helping you focus on what brings you alive, such as patient connections or personal growth, rather than external metrics like income or status.About the Show:Succeed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest Hosts: Carl Richards is a financial storyteller, artist, and author known for his "Sketch Guy" column in the New York Times. With decades in the financial sphere, he helps people re-imagine wealth through simple sketches and profound insights. His new book "Your Money: Re-Imagining Wealth in Simple Sketches," challenges conventional views on money. Carl draws from global experiences, including four years in New Zealand, and hosts retreats focused on values, risk, and decision-makingWebsite: https://behaviorgap.com Dr. Cobin Soelberg is a private practice anesthesiologist and principal advisor at Greeley Wealth Management. He focuses on financial strategies, personal development, and holistic success for healthcare professionals. Drawing from his own career, he integrates practical advice with deeper reflections on wealth and well-being. Website: GreeleyWealthManagement.com This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why has America struggled so much to effectively manage the opioid use crisis? One of the answers, as you'll learn in this eye-opening episode of Raise the Line, is rooted in laws and attitudes from the early 20th century that removed addiction from the realm of medicine and defined it as a moral failing.  “The federal Harrison Act of 1914 forbade any physician from prescribing opioids to people with addiction, so it became more the purview of law enforcement or behavioral health or religion,” says Dr. Melody Glenn, who regularly confronts the consequences of this history during shifts in the emergency department at Banner-University Medical Center in Tucson, Arizona. And as Glenn explains to host Caleb Furnas, the resulting stigma associated with addiction has extended to the treatments for it as well, especially methadone, despite its effectiveness. Drawing on her dual expertise in emergency and addiction medicine, Glenn dispels misconceptions that medication-assisted treatment merely replaces one addiction with another, and emphasizes that harm reduction is critical to saving lives. Her desire to break prevailing stigmas led her to discover the story of Dr. Marie Nyswander, who pioneered methadone maintenance therapy in the 1960s and is featured in Dr. Glenn's new book, Mother of Methadone: A Doctor's Quest, a Forgotten History, and a Modern-Day Crisis. You'll leave this instructive interview understanding the roots of our flawed approach to addiction treatment, meeting an overlooked pioneer in the field, and admiring a devoted and compassionate physician who is following in her footsteps.  Mentioned in this episode:Banner-University Medical CenterMother of Methadone book If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring an interview with Dr Laura Huppert, including the following topics: General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00) Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44) Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30) Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13) Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25) CNS penetration and activity of ADCs in the treatment of breast cancer (22:27) Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24) Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05) Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51) Ongoing evaluation of ADCs in the localized disease setting (35:42) Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38) CME information and select publications

Send us a textWhen Washington shuts its doors, your practice can't afford to blink. What happens when Medicare payments slow—or telehealth rules vanish overnight?Welcome to Medical Money Matters. If you're like most medical group leaders, your attention is already divided between patients, staff, regulations, and operations. Add a federal government shutdown to that mix, and suddenly you're facing a silent threat to your cash flow, your staffing, and the systems you count on to deliver care.Today, we're breaking down exactly how the current government shutdown affects medical practices—and not just in the obvious ways. We'll look at how Medicare payments might be delayed, what flexibilities have quietly disappeared, and how you can proactively shield your practice from the ripple effects. Whether you're a small independent clinic or a large multispecialty group, this episode is designed to help you think clearly and act strategically. Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: http://21978609.hs-sites.com/newletter-subscriber Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Find it here: https://healtheps.com/physicians-edge-mastering-business-finance-in-your-medical-practice/  Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/

For this episode hosts Andy and John are joined by guests Patricia Capone, Marcus Robinson and Aatish Patel to discuss Fear. Specifically answering the question "what fearss have you overcome to get to where you are today?" Don't forget we are the official podcast of the American College of Osteopathic Emergency Physicians, visit acoep.org today to learn more about an upcoming CME event where you'll get a chance to see your favorite EM podcast LIVE and in person.

Josh has 20 years in Public SafetyCurrently doing crisis prevention instructionWe often don't get any education in med school or PA school in how to communicate well with patients or how to de-escalate their behaviorCode greys are the behavior health emergency response; someone has some concern that a patient is escalating to potentially violent behavior and a team will respondStaff safety is priorityWe are there to provide excellent medical care, if it's safe to do soWe recommend calling code greys earlier to avoid worsening scenarios Code grey assures staff safety then de-escalation of the patientRecognizing when you need help with patient interaction from some other staff member is importantTypically, negative behavior is a result of an unmet need or wantRationally detachGive people options, this helps give them a measure of control when they feel out of controlGet consent to do a physical exam, taking that extra few seconds to explain what you're doing and getting that quick permission goes a long wayWe forget that we ignore many social norms in the ED, patients may not be used to thisAlways introduce yourselfA huge component to de-escalation of patients with negative and violent behaviors is that, if not done properly, they are a primary source of burnout. They become a huge negative experience that it sticks with you, not to even speak of the potential for an injury. Avoiding these negative experiences at all costs will be key to thriving in emergency medicineJosh talks about a severe ankle injury he sustained and how he found a way to keep helping people anyway. He talks about how he strived to get the struggling people back connected to community. He helped them re-establish trust in others so that they could accept helpWe talk about the resources available for financially struggling patientsSupport the showEverything you hear today from myself and my guests is opinion only and doesn't represent any organizations or companies that any of us are affiliated with. The stories you hear have been modified to protect patient privacy and any resemblance to real individuals is coincidental. This is for educational and entertainment purposes only and should not be taken as medical advice nor used to diagnose any medical or healthcare conditions. This is not medical advice. If you have personal health concerns, please seek professional care. Full show notes can be found here: Episodes - Practical EMS - Content for EMTs, PAs, ParamedicsMost efficient online EKG course here: Practical EKG Interpretation - Practical EMS earn 4 CME and learn the fundamentals through advanced EKG interpretation in under 4 hours. If you want to work on your nutrition, increase your energy, improve your physical and mental health, I highly recommend 1st Phorm. Check them out here so they know I sent you. 1st Phorm | The Foundation of High Performance Nutrition

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics: Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00) Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18) Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10) CME information and select publications

Have you ever opened a CT scan, MRI, or X-ray… and felt that wave of uh-oh? That moment of self-doubt when you're not 100% sure what you're looking at? You're not alone—and today's episode is for you.In this episode, Tracy introduces you to Guardian Lite, an interactive, case-based CME platform that helps clinicians build real imaging confidence. Whether you're a new grad or stepping into a new specialty, Guardian Lite helps you see it, know it, and catch it before it matters most in real life.Here's what you'll learn:

Dave Garrison is the CEO of Garrison Growth, equipping leaders to generate buy-in and get the best results from their teams. Dave is a seasoned executive with experience as a board member at organizations like Ameritrade and as CEO of public and venture backed firms. A sought-after speaker and workshop leader, Dave has led hundreds of sessions for profit and non-for-profit organizations and for members of Young Presidents Organization both globally and locally. These sessions are top rated and have been attended by thousands worldwide. He has also been a guest lecturer at leading business schools. He holds an MBA from Harvard Business School.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

“We don't view a person with chronic pain as someone who has a chronic illness and the effect of that is we can't follow patients continuously over prolonged periods of time,” says Dr. Jacob Hascalovici, a neurologist and pain specialist based in New York City.  In co-founding Bliss Health, Dr. Jacob, as he is known, has set out to create a continuous care model for chronic pain treatment that matches the approach taken for patients with diabetes or high blood pressure. The Bliss Health formula includes an initial meeting with a physician that produces a care plan; remote therapeutic monitoring on an ongoing basis; and a monthly meeting with a nurse to review data and determine next steps, including additional appointments with physicians as needed.  All of this occurs via a digital platform which provides a welcome option for patients with mobility issues and can fill gaps in access to specialists, especially in rural areas. Dr. Jacob is also hoping to make chronic pain patents feel respected, which is not always the case in their encounters with the healthcare system. “Because pain is not something that can be seen or measured, oftentimes patients feel marginalized, dismissed and disempowered by providers.” Join Raise the Line host Lindsey Smith for a valuable conversation that also touches on policy changes that could strengthen telemedicine, and has details on the first non-opioid based pain medication to receive FDA approval in over 20 years.Mentioned in this episode:Bliss Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring an interview with Dr Ghayas Issa, including the following topics: Mechanism of action and efficacy of menin inhibitors (0:00) Presentation and management of differentiation syndrome (13:31) Role of menin inhibitors in other cancers (18:19) Case: A woman in her mid 40s with KMT2A-rearranged acute myeloid leukemia (AML) after treatment for breast cancer (20:51) Mechanisms of resistance to menin inhibition in AML (26:53) Case: A woman in her early 70s with monocytic AML and multiple mutations including NPM1 experienced complete response with ziftomenib (32:31) Mechanism of action of menin inhibitors as differentiation agents (38:05) Similarities and differences between approved and investigational menin inhibitors under clinical development for the treatment of AML (45:55) Dual targeted therapy and other novel treatment approaches under clinical evaluation with menin inhibitors (51:25) Other investigational therapeutic strategies in AML (54:39) CME information and select publications

Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

Welcome to Perimenopause WTF!, brought to you by ⁠Perry⁠—the #1 perimenopause app and safe space for connection, support, and new friendships during the menopause transition. You're not crazy, and you're not alone!  Download the free Perry App on ⁠Apple⁠ or ⁠Android⁠ and join our live expert talks, receive evidence-based education, connect with other women, and simplify your perimenopause journey.In today's episode, “Breaking the Stigma: Perimenopause & Menopause for Millennials,” Dr. Adrienne Mandelberger and Lauren Tetenbaum, LCSW, explore the Millennial perspective on navigating this life stage. While this generation approaches perimenopause and menopause with more openness, stigma and misinformation still persist. Join us as they answer community questions and discuss how Millennials can help reshape the workplace culture, or their thoughts on hormone blood testing, HRT awareness, menopause education and health support as “standard” in maternity and mental health care.

Dr. Rajesh Rao discusses the risk factors for epiretinal membrane formation in patients with diabetes mellitus with Dr. Shinji Kakihara, first author of the Ophthalmology Science article, “Epiretinal Membrane Is Associated with Diabetic Retinopathy Severity and Cumulative Anti-VEGF Injections.” Epiretinal Membrane Is Associated with Diabetic Retinopathy Severity and Cumulative Anti-VEGF Injections. Kakihara, Shinji et al. Ophthalmology Science, Volume 5, Issue 3. If you are unable to travel to AAO 2025, you can still enjoy the unparalleled program by registering for AAO 2025 Virtual. Get access to the annual meeting course and sessions recorded in Orlando, on-demand-only content specifically for the online platform, videos and posters, and CME credits. Learn more and register at aao.org/RegNow. Ophthalmology journal events at AAO 2025: ·        Peer Review Masterclass: A Practical Workshop for Journal Authors and Reviewers: Become a peer reviewer for the Academy's Ophthalmology journal, the leading journal in the field, and its companion journals, Ophthalmology Retina, Ophthalmology Glaucoma, and Ophthalmology Science. Dr. Emily Schehlein and Dr. Aaki Shukla, highly experienced reviewers and authors for various journals, will lead this free interactive workshop. Sponsored by Elsevier. ·        The Year in Literature: Editor's Choice Highlights From the Ophthalmology Journal Family: Join Ophthalmology's Editor-in-Chief, Dr. Russell Van Gelder, as he presents the top Ophthalmology articles on Sunday October 19 at 9:45am. Search “SYM31” in the Mobile Meeting Guide for more information. ·        Meet the Editor: Join us for an intimate conversation with Ophthalmology Editor-in-Chief, Dr. Russ Van Gelder, during the American Academy of Ophthalmology Annual Meeting. This special meet and greet offers ophthalmologists, residents, and researchers a unique chance to connect directly with one of our field's most influential editorial voices. Sunday, October 19, 3:30-4:30 pm, Academy Hub at the exhibit hall.

Featuring a slide presentation and related discussion from Dr Ghayas Issa, including the following topics: Evolution of menin inhibitors for acute myeloid leukemia (AML) (0:00) Side effects of menin inhibition (10:54) Mechanisms of resistance to menin inhibition in AML (15:08) CME information and select publications

Are you ready to move beyond writing needs assessments and step into the creative, story-driven side of CME—without losing the clients or confidence you've already built?Many CME writers start with needs assessments. They're structured, strategic, and an excellent way to learn the landscape. But what happens when you feel ready for more? When you want to create content that sparks learning, integrates clinical insight, and allows your creativity to shine? In this hot seat coaching episode, we meet Zsuzsa Csik, an anesthesiologist and critical care physician turned CME writer, who's navigating that exact transition—and learning how to position herself for content work while building a sustainable freelance business.By listening, you'll discover:How to strategically signal to clients that you're ready for content creation projects.Practical ways to use your clinical or scientific background as a bridge, not a barrier, to new opportunities.Simple positioning tactics to align your current work with your long-term professional goals.Press play now to learn how to move from analysis to creation, and start shaping the CME writing career you really want.Mentioned in this episode:CMEpaloozaCMEpalooza Fall is a 1-day event scheduled for Wednesday, October 22, that will feature a series of sessions relevant across the CME/CE spectrum. Broadcasts will stream live on the LIVE page of this website and be available for viewing shortly after their conclusion on the Archive page. There is no charge to view or participate in any of these sessions.This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

While genetic testing has replaced muscle biopsy in the diagnosis of many genetic myopathies, clinical assessment and the integration of clinical and laboratory findings remain key elements for the diagnosis and treatment of muscle diseases. In this episode, Casey Albin, MD, speaks with Margherita Milone, MD, PhD, FAAN, FANA, author of the article “A Pattern Recognition Approach to Myopathy” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Milone is a professor of neurology and the director of the Muscle Pathology Laboratory at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Additional Resources Read the article: A Pattern Recognition Approach to Myopathy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello, this is Dr Casey Albin. Today I'm interviewing Dr Margherita Milone on her article on a pattern recognition approach to myopathy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Welcome to the podcast, Dr Milone. Thank you so much for joining us. I'll start off by having you introduce yourself to our listeners. Dr Milone: Hello Casey, thank you so much for this interview and for bringing the attention to the article on muscle diseases. So, I'm Margherita Milone. I'm one of the neuromuscular neurologists at Mayo Clinic in Rochester. I have been interested in muscle disorders since I was a neurology resident many years ago. Muscle diseases are the focus of my clinical practice and research interest. Dr Albin: Wonderful. Thank you so much. When I think about myopathies, I generally tend to think of three large buckets: the genetic myopathy, the inflammatory myopathies, and then the necrotizing myopathies. Is that a reasonable approach to conceptualizing these myopathies? Dr Milone: Yeah, the ideology of the myopathies can be quite broad. And yes, we have a large group of genetic muscle diseases, which are the most common. And then we have immune-mediated muscle diseases, which include inflammatory myopathies as well as some form of necrotizing myopathies. Then we have some metabolic myopathies, which could be acquired or could be genetic. And then there are muscle diseases that are due to toxins as well as to infection. Dr Albin: Wow. So, lots of different etiologies. And that really struck me about your article, is that these can present in really heterogeneous ways, and some of them don't really read the rule book. So, we have to have a really high level of suspicion, for someone who's coming in with weakness, to remember to think about a myopathy. One of the things that I like to do is try to take us through a little bit of a case to sort of walk us through how you would approach if someone comes in. So, let's say you get, you know, a forty-year-old woman, and she's presenting with several months of progressive weakness. And she says that even recently she's noted just a little bit of difficulty swallowing. It feels to her like things are getting stuck. What are some of the things when you are approaching the history that would help you tease this to a myopathy instead of so many other things that can cause a patient to be weak? Dr Milone: Yes. So, as you mentioned, people who have a muscle disease have the muscle weakness often, but the muscle weakness is not just specific for a muscle disease. Because you can have a mass weakness in somebody who has a neurogenic paralysis. The problem with diagnosis of muscle diseases is that patients with these disorders have a limited number of symptom and sign that does not match the large heterogeneity of the etiology. So, in someone who has weakness, that weakness could represent a muscle disease, could represent an anterior horn cell disease, could represent a defect of neuromuscular junction. The clinical history of weakness is not sufficient by itself to make you think about a muscle disease. You have to keep that in the differential diagnosis. But your examination will help in corroborating your suspicion of a muscle disease. Let's say if you have a patient, the patient that you described, with six months' history of progressive weakness, dysphagia, and that patient has normal reflexes, and the patient has no clinical evidence for muscle fatigability and no sensory loss, then the probability that that patient has a myopathy increases. Dr Albin: Ah, that's really helpful. I'm hearing a lot of it is actually the lack of other findings. In some ways it's asking, you know, have you experienced numbness and tingling? And if not, that's sort of eliminating that this might not be a neuropathy problem. And then again, that fatigability- obviously fatigability is not specific to a neuromuscular junction, but knowing that is a hallmark of myasthenia, the most common of neuromuscular disorders. Getting that off the table helps you say, okay, well, it's not a neuromuscular junction problem, perhaps. Now we have to think more about, is this a muscle problem itself? Are there any patterns that the patients describe? I have difficulty getting up from a chair, or I have difficulty brushing my hair. When I think of myopathies, I historically have thought of, sort of, more proximal weakness. Is that always true, or not so much? Dr Milone: Yeah. So, there are muscle diseases that involve predominantly proximal weakness. For example, the patient you mentioned earlier could have, for example, an autoimmune muscle disease, a necrotizing autoimmune myopathy; could have, perhaps, dermatomyositis if there are skin changes. But a patient with muscle disease can also present with a different pattern of weakness. So, myopathies can lead to this weakness, and foot drop myopathies can cause- can manifest with the weakness of the calf muscles. So, you may have a patient presenting to the clinic who has no the inability to stand on tiptoes, or you may have a patient who has just facial weakness, who has noted the difficulty sealing their lips on the glasses when they drink and experiencing some drooling in that setting, plus some hand weakness. So, the muscle involved in muscle diseases can vary depending on the underlying cause of the muscle disease. Dr Albin: That's really helpful. So, it really is really keeping an open mind and looking for some supporting features, whether it's bulbar involvement, extraocular eye muscle involvement; looking, you know, is it proximal, is it distal? And then remembering that any of those patterns can also be a muscle problem, even if sometimes we think of distal being more neuropathy and proximal myopathy. Really, there's a host of ranges for this. I really took that away from your article. This is, unfortunately, not just a neat way to box these. We really have to have that broad differential. Let me ask another question about your history. How often do you find that patients complain of, sort of, muscular cramping or muscle pain? And does that help you in terms of deciding what type of myopathy they may have? Dr Milone: Many patients with muscle disease have muscle pain. The muscle pain could signal a presence of inflammation in skeletal muscle, could be the result of overuse from a muscle that is not functioning normally. People who have myotonia experience muscle stiffness and muscle pain. Patients who have a metabolic myopathy usually have exercise-induced muscle pain. But, as we know, muscle pain is also very nonspecific, so we have to try to find out from the patient in what setting the pain specifically occurs. Dr Albin: That's really helpful. So, it's asking a little bit more details about the type of cramping that they have, the type of pain they may be experiencing, to help you refine that differential. Similarly, one of the things that I historically have always associated with myopathies is an elevation in the CK, or the creatinine kinase. How sensitive and specific is that, and how do you as the expert sort of take into account, you know, what their CK may be? Dr Milone: So, this is a very good point. And the elevation of creatine kinase can provide a clue that the patient has a muscle disease, but it is nonspecific for muscle disease because we know that elevation of creatine kinase can occur in the setting of a neurogenic process. For example, we can see elevation of the creatine kinase in patients who have ALS or in patients who have spinal muscular atrophy. And in these patients---for example, those with spinal muscular atrophy---the CK elevation can be also of significantly elevated up to a couple of thousand. Conversely, we can have muscle diseases where the CK elevation does not occur. Examples of these are some genetic muscle disease, but also some acquired muscle diseases. If we think of, for example, cases where inflammation in the muscle occurs in between muscle fibers, more in the interstitium of the muscle, that disease may not lead to significant elevation of the CK. Dr Albin: That's super helpful. So, I'm hearing you say CK may be helpful, but it's neither completely sensitive nor completely specific when we're thinking about myopathic disorders. Dr Milone: You are correct. Dr Albin: Great. So, coming back to our patients, you know, she says that she has this dysphasia. How do bulbar involvement or extraocular eye movement involvement, how do those help narrow your differential? And what sort of disorders are you thinking of for patients who may have that bulbar or extraocular muscle involvement? Dr Milone: Regarding dysphagia, that can occur in the setting of acquired myopathies relatively frequent; for example, in inclusion body myositis or in other forms of inflammatory myopathy. Your patient, I believe, was in their forties, so it's a little bit too young for inclusion body myositis. Involvement of the extraocular muscles is usually much more common in genetic muscle diseases and much less frequent in hereditary muscle disease. So, if there is involvement of the extraocular muscles, and if there is a dysphagia, and if there is a proximal weakness, you may think about oculopharyngeal muscular dystrophy, for example. But obviously, in a patient who has only six months of history, we have to pay attention of the degree of weakness the patient has developed since the symptom onset. Because if the degree of weakness is mild, yes, it could still be a genetic or could be an acquired disease. But if we have a patient who, in six months, from being normal became unable to climb stairs, then we worry much more about an acquired muscle disease. Dr Albin: That's really helpful. So, the time force of this is really important. And when you're trying to think about, do I put this in sort of a hereditary form of muscle disease, thinking more of an indolent core, something that's going to be slowly progressive versus one of those inflammatory or necrotizing pathologies, that's going to be a much more quick onset, rapidly progressive, Do I have that right? Dr Milone: In general, the statement is correct. They tend, acquired muscle disease, to have a faster course compared to a muscular dystrophy. But there are exceptions. There have been patients with immune mediated necrotizing myopathy who have been misdiagnosed as having limb-girdle muscular dystrophy just because the disease has been very slowly progressive, and vice versa. There may be some genetic muscle diseases that can present in a relatively fast way. And one of these is a lipid storage myopathy, where some patients may develop subacutely weakness, dysphagia, and even respiratory difficulties. Dr Albin: Again, I'm hearing you say that we really have to have an open mind that myopathies can present in a whole bunch of different ways with a bunch of different phenotypes. And so, keeping that in mind, once you suspect someone has a myopathy, looking at the testing from the EMG perspective and then maybe laboratory testing, how do you use that information to guide your work up? Dr Milone: The EMG has a crucial role in the diagnosis of muscle diseases. Because, as we said earlier, weakness could be the result of muscle disease or other form of neuromuscular disease. If the EMG study will show evidence of muscle disease supporting your diagnostic hypothesis, now you have to decide, is this an acquired muscle disease or is this a genetic muscle disease? If you think that, based on clinical history of, perhaps, subacute pores, it is more likely that the patient has an acquired muscle disease, then I would request a muscle biopsy. The muscle biopsy will look for structural abnormalities that could help in narrowing down the type of muscle disease that the patient has. Dr Albin: That's really helpful. When we're sending people to get muscle biopsies, are there any tips that you would give the listeners in terms of what site to biopsy or what site, maybe, not to biopsy? Dr Milone: This is a very important point. A muscle biopsy has the highest diagnostic yield if it's done in a muscle that is weak. And because muscle diseases can result in proximal or distal weakness, if your patient has distal weakness, you should really biopsy a distal muscle. However, we do not wish to biopsy a muscle that is too weak, because otherwise the biopsy sample will result just in fibrous and fatty connected tissue. So, we want to biopsy a muscle that has mild to moderate weakness. Dr Albin: Great. So, a little Goldilocks phenomenon: has to be some weak, but not too weak. You got to get just the right feature there. I love that. That's a really good pearl for our listeners to take. What about on the flip side? Let's say you don't think it's an acquired a muscular disease. How are you handling testing in that situation? Dr Milone: If you think the patient has a genetic muscle disease, you pay a lot of attention to the distribution of the weakness. Ask yourself, what is the best pattern that represent the patient's weakness? So, if I have a patient who has facial weakness, dysphagia, muscle cramping, and then on examination represent myotonia, then at that point we can go straight to a genetic test for myotonic dystrophy type one. Dr Albin: That's super helpful. Dr Milone: So, you request directly that generic test and wait for the result. If positive, you will have proof that your diagnostic hypothesis was correct. Dr Albin: You're using the genetic testing to confirm your hypothesis, not just sending a whole panel of them. You're really informing that testing based on the patient's pattern of weakness and the exam findings, and sometimes even the EMG findings as well. Is that correct? Dr Milone: You are correct, and ideally, yes. And this is true for certain muscle diseases. In addition to myotonic dystrophy type one, for example, if you have a patient who has fascial scapulohumeral muscular weakness, you can directly request a test for FSHD. So, the characterization of the clinical phenotype is crucial before selecting the genetic test for diagnosis. Dr Albin: Wonderful. Dr Milone: However, this is not always possible, because you may have a patient who has just a limb-girdle weakness, and the limb-girdle weakness can be limb-girdle muscular dystrophy. But we know that there are many, many types of limb-girdle muscular dystrophies. Therefore, the phenotype is not sufficient to request specific genetic tests for one specific form of a limb-girdle muscular dystrophy. And in those cases, more complex next-generation sequencing panels have a higher chance of providing the answer. Dr Albin: Got it, that makes sense. So, sometimes we're using a specific genetic test; sometimes, it is unfortunate that we just cannot narrow down to one disease that we might be looking for, and we may need a panel in that situation. Dr Milone: You are correct. Dr Albin: Fantastic. Well, as we wrap up, is there anything on the horizon for muscular disorders that you're really excited about? Dr Milone: Yes, there are a lot of exciting studies ongoing for gene therapy, gene editing. So, these studies are very promising for the treatment of genetic muscle disease, and I'm sure there will be therapists that will improve the patient's quality of life and the disease outcome. Dr Albin: It's really exciting. Well, thank you again. Today I've been interviewing Dr Margarita Malone on her article on a pattern recognition approach to myopathy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining us today. And thank you, Dr Milone. Dr Milone: Thank you, Casey. Very nice chatting with you about this. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

How can Navy SEAL training principles transform medical practice amid rising uncertainty? In this special guest-hosted episode of Succeed in Medicine, John Schneider interviews Rich Diviney, as he recounts developing The Attributes during his time leading selection for SEAL Team Six, distinguishing between teachable skills and innate qualities that underpin performance under stress. Listeners learn about the 41 attributes assessment available at theattributes.com, which reveals personal "dimmer switch" settings to enhance self-awareness without judgment. The discussion bridges military and medical worlds, exploring how ER physicians and SEALs share traits like compartmentalization, while roles like general practitioners demand higher empathy. Transitioning to Masters of Uncertainty, Rich delves into identity's role in performance, advocating "I am" statements tied to attributes for resilience during career shifts. He introduces the "Moving Horizons" tool to generate personal certainty by chunking challenges, drawing from SEAL Hell Week and Apollo missions to show how it dissipates fear through neuroplasticity. The episode culminates in dynamic subordination—a fluid leadership model where teams adapt like an amoeba, empowering all members in uncertain environments, with parallels to surgical teams. Essential listening for physicians navigating change, burnout, and team dynamics.Three Actionable Takeaways:Assess Your Attributes – Visit theattributes.com to take the free assessment and identify your unique strengths and blind spots. Use this self-awareness to match roles that align with your innate qualities, enhancing performance in high-stress medical settings.Practice Moving Horizons – In moments of uncertainty, ask: What do I know? What can I control? Choose a short, achievable horizon (e.g., next 10 breaths or task) to generate dopamine and focus, building resilience through daily practice like workouts.Foster Dynamic Subordination – Lead by behavior, not title: Create environments where the most competent person steps up, and others support. In teams, use first names and empower voices to optimize decision-making in fluid, high-stakes scenarios like surgery or emergencies.About the Show:Succeed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest Hosts:· John Schneider – An academic neurosurgeon and physician coach, guest hosts the Succeed in Medicine podcast, interviewing former Navy SEAL Rich Diviney. He trains residents, values self-discovery through assessments, and champions dynamic subordination in teams. Fascinated by human behavior, Schneider initially aimed to be an economist before pursuing medicine.Rich Diviney – A retired Navy SEAL Commander with over 20 years of service and 13 deployments, authored The Attributes and Masters of Uncertainty. As a performance consultant, he advises high-performing teams, using his SEAL Team Six experience to develop assessments and strategies for mastering uncertainty and enhancing self-awarenessConnect with Rich Diviney:Website:    https://theattributes.comEmail:    rich@theattributes.com  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode, we dive into the ins and outs of the rheumatology musculoskeletal ultrasound certification process—what it takes to log 150 scans, meet CME requirements, and ultimately sit for the exam. We're joined by Dr. Liudmila Kastsianok, who shares her insights on how ultrasound is reshaping clinical practice, from enhancing diagnostic accuracy to opening new avenues in research. We also explore how incorporating ultrasound into routine care can deepen the physician-patient relationship and improve communication. Finally, Dr. Kastsianok offers her perspective on where the field is headed and why ultrasound is becoming an essential skill for the next generation of rheumatologists. 

In recent months, public health advocates in the United States have raised concerns about proposed changes to vaccine policy, cuts to food assistance programs, rollbacks of environmental protections and reductions in public health staffing. Chief among them has been Dr. Georges Benjamin who, as executive director of the American Public Health Association (APHA) since 2002, has led national efforts to create a healthier America. Raise the Line host Lindsey Smith recently sat down with Dr. Benjamin to understand more about the current state of public health and explore the path forward, and learned that a top priority for APHA is battling the misinformation that Dr. Benjamin believes is fueling support for many of these changes. “The challenge we have right now is that as a society, we've gone into our little corners and live in our own ecosystems. More people are getting their information from a single source and they're not validating that information to make sure that it's true.” Tune into this thoughtful and timely conversation to hear Dr. Benjamin's advice for curbing the spread of misinformation, how APHA is trying to help people understand the value of public health initiatives, and what the U.S. can learn from other countries about improving public health. Mentioned in this episode:American Public Health Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Featuring perspectives from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics: Introduction: View from Outer Space (0:00) Hormone Receptor-Positive Breast Cancer (6:23) HER2-Positive Breast Cancer (40:54) Triple-Negative Breast Cancer (52:48) CME information and select publications

Send us a textDebt makes most doctors nervous. But what if avoiding financing is actually holding your practice back?Welcome to Medical Money Matters, the podcast where we tackle the intersection of medicine, money, and management—helping you run your practice like the business it is. Today, we're diving into a topic that physicians often avoid but can't afford to ignore: debt and financing for medical practices.If the very mention of debt makes your stomach turn, you're not alone. Most physicians are naturally conservative when it comes to money—and understandably so. You've been trained to avoid risk. To make decisions based on data, not gut feelings. And let's be honest: medical school didn't prepare you for amortization tables or capital structure discussions.But here's the thing. Avoiding debt doesn't mean avoiding risk. In fact, in some cases, avoiding financing might be the most expensive decision your practice can make.Today, we'll explore what financing options are available to medical groups, break down the difference between debt and equity financing, and help you think clearly about when—and how—to use capital as a strategic tool. By the end of this episode, you'll have a framework for making smart financial decisions that support both the clinical mission and the long-term stability of your organization.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: http://21978609.hs-sites.com/newletter-subscriber Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Find it here: https://healtheps.com/physicians-edge-mastering-business-finance-in-your-medical-practice/ Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/

Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. CME information and select publications here.

GOLD Updates, Novel Treatments, and Managing Comorbidities in COPD Care Level up your COPD care with practical, evidence-based strategies. Learn how to confirm airflow obstruction with spirometry (and use LLN/Z-scores thoughtfully), stage patients with the A/B/E framework, and build treatment around long-acting bronchodilation—adding ICS selectively based on exacerbations and eosinophils. We'll highlight the nonpharmacologic moves that change outcomes (smoking cessation, vaccination, pulmonary rehab, oxygen when indicated), when to reach for add-ons (azithromycin, roflumilast), how to approach chronic hypercapnia with home NIV, and what's new (hello, ensifentrine). Pulmonologist and longtime Curbsiders member Dr. Cyrus Askin (@Askins_Razor ) returns to share real-world pearls for diagnosing, treating, and managing comorbidities in COPD. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 Diagnostic Workup Understanding the Ratio, LLN/Z-Scores, and Equity Symptom abd Risk Staging (A/B/E) Case 2 Foundational Care  Initial Inhaler Strategy  Progression & Hypercapnia: NIV & Adherence Counseling Add-On Pharmacologic Options for Frequent Exacerbators What's New and Emerging Comorbidities and When to Refer  Take-Home Points Recap Plugs, CME, and Credits Credits Written and produced by Paul Wurtz MD. Show notes, cover art, and infographic also created by Paul Wurtz MD. Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cyrus Askin MD   Sponsor - Freed Use code: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor - Grammarly Sign up for FREE and experience how Grammarly can elevate your professional writing from start to finish. Visit Grammarly.com/podcast Sponsor -Locumstory Learn about locums and get insights from real-life physicians, PAs and NPs at Locumstory.com

In this episode, hosts Drs. Temara Hajjat and Jenn Lee talk to Dr. Jordan Whatley, Assitant Professor of Pediatrics at the Medical University of South Carolina and pediatric gastroenterologist at Shawn Jenkins Children's Hospital in Charleston, South Carolina. We discuss how multi-specialty clinics focusing on children with tracheostomy and ventilator dependence can improve clinical care.Learning Objectives:Describe the reasons children may require a tracheostomy and home mechanical ventilation.Explain multidisciplinary structure and purpose of an aerodigestive clinic in managing complex pediatric patients. Describe the gastroenterologist's role in evaluating and managing GERD, feeding intolerance, and nutritional needs in children with trach/vent dependence. Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Featuring case presentations and related discussion from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics: Case: A woman in her mid 50s with localized HR-negative, HER2-positive breast cancer — Dr Tolaney (0:00) Case: A woman in her mid 40s with localized HR-positive breast cancer with a germline BRCA2 mutation — Dr Tolaney (7:08) Case: A woman in her early 30s with HR-negative, HER2-positive metastatic breast cancer with one isolated liver metastasis — Dr Tolaney (11:30) Case: A woman in her early 50s with metastatic triple-negative breast cancer — Dr Tolaney (17:52) Case: A woman in her early 30s with localized HR-positive, HER2-negative breast cancer — Dr Hurvitz (31:49) Case: A woman in her early 60s with HR-positive, HER2-negative metastatic breast cancer with concurrent PIK3CA and ESR1 mutations — Dr Hurvitz (40:39) Case: A woman in her early 40s with recurrent HR-positive advanced breast cancer with a PIK3CA mutation — Dr Hurvitz (51:28) Case: A woman in her early 50s with HR-positive, HER2-negative breast cancer eligible for the SERENA-6 switching strategy — Angela DeMichele, MD, MSCE (58:41) CME information and select publications

In this episode, Sam Ashoo, MD interviews Evan Dvorin, MD about the dangers of short term steroid use.Background & Regional DifferencesDr. Dvorin's clinical journey from New England to New Orleans. Noticing increased use of corticosteroids for common conditions in the Southeast. Discussion of how steroid prescribing practices vary by region and setting.Inappropriate Steroid UseCommon conditions where steroids are often inappropriately prescribed (sinus infections, bronchitis, sciatica, rashes, plantar fasciitis, etc.). Trends showing increased steroid prescribing over time. Similar patterns observed in emergency, urgent care, and primary care settings.Risks and Side Effects of Short-Term Steroid UseShort-term steroids can cause significant side effects: infection, sepsis, bone fractures, thromboembolism, psychiatric effects, hyperglycemia. Dose-response relationship: higher doses and repeated use increase risks. Some side effects (e.g., bone loss) may persist beyond two months.Patient Communication & Shared Decision-MakingImportance of discussing risks with patients, tailored to individual risk factors (e.g., diabetes, psychiatric history, age). Strategies for educating patients and managing expectations. The role of patient education videos and resources.Impact of Provider Education & Quality MetricsOchsner Health's initiatives to reduce inappropriate steroid use. Use of CME, quality dashboards, and feedback to clinicians. Evidence that education and reporting can reduce unnecessary prescriptions.Special Populations & ScenariosConsiderations for pediatric patients and repeated dosing. Challenges when specialists recommend steroids for certain conditions (e.g., sciatica, neurosurgery cases). The need for evidence-based practice and inter-provider communication.Medical-Legal ConsiderationsLawsuits related to steroid side effects (e.g., fat atrophy, infection). Importance of documentation and informed consent.Alternatives & Symptom ManagementFocusing on treating the patient's most bothersome symptoms. Non-steroid options and the value of patient education about illness duration and expectations.ResourcesMention of Dr. Dvorin's educational video on corticosteroid side effects (available on YouTube). Reminder of EB Medicine's journals and resources for further learning.ConclusionKey takeaway: “Do no harm” and practice evidence-based medicine. Encouragement for clinicians to review their prescribing habits and educate patients.Ochsner "Side effects from corticosteroids" Video: https://www.youtube.com/watch?v=PdMJ9HYxkck

Solar storms are inevitable; disaster isn't. We explore the physics of flares and CMEs, historical extremes, and realistic defenses—detection, delay, and planetary-scale shielding—to weather the Sun's worst days.Watch my exclusive video The Fermi Paradox - Civilization Extinction Cycles: https://nebula.tv/videos/isaacarthur-the-fermi-paradox-civilization-extinction-cyclesGet Nebula using my link for 40% off an annual subscription: https://go.nebula.tv/isaacarthurGet a Lifetime Membership to Nebula for only $300: https://go.nebula.tv/lifetime?ref=isaacarthurUse the link https://gift.nebula.tv/isaacarthur to give a year of Nebula to a friend for just $36.Visit our Website: http://www.isaacarthur.netJoin Nebula: https://go.nebula.tv/isaacarthurSupport us on Patreon: https://www.patreon.com/IsaacArthurSupport us on Subscribestar: https://www.subscribestar.com/isaac-arthurFacebook Group: https://www.facebook.com/groups/1583992725237264/Reddit: https://www.reddit.com/r/IsaacArthur/Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.SFIA Discord Server: https://discord.gg/53GAShECredits:Solar Flares and Coronal Mass Ejections - Defending Earth from Our Own StarWritten, Produced & Narrated by: Isaac ArthurGraphics: Mafic Studios, Sergio BoteroSelect imagery/video supplied by Getty Images Music Courtesy of Aerium, Stellardrone, Chris Zabriskie, and Epidemic Sound http://epidemicsound.com/creatorSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Solar storms are inevitable; disaster isn't. We explore the physics of flares and CMEs, historical extremes, and realistic defenses—detection, delay, and planetary-scale shielding—to weather the Sun's worst days.Watch my exclusive video The Fermi Paradox - Civilization Extinction Cycles: https://nebula.tv/videos/isaacarthur-the-fermi-paradox-civilization-extinction-cyclesGet Nebula using my link for 40% off an annual subscription: https://go.nebula.tv/isaacarthurGet a Lifetime Membership to Nebula for only $300: https://go.nebula.tv/lifetime?ref=isaacarthurUse the link https://gift.nebula.tv/isaacarthur to give a year of Nebula to a friend for just $36.Visit our Website: http://www.isaacarthur.netJoin Nebula: https://go.nebula.tv/isaacarthurSupport us on Patreon: https://www.patreon.com/IsaacArthurSupport us on Subscribestar: https://www.subscribestar.com/isaac-arthurFacebook Group: https://www.facebook.com/groups/1583992725237264/Reddit: https://www.reddit.com/r/IsaacArthur/Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.SFIA Discord Server: https://discord.gg/53GAShECredits:Solar Flares and Coronal Mass Ejections - Defending Earth from Our Own StarWritten, Produced & Narrated by: Isaac ArthurGraphics: Mafic Studios, Sergio BoteroSelect imagery/video supplied by Getty Images Music Courtesy of Aerium, Stellardrone, Chris Zabriskie, and Epidemic Sound http://epidemicsound.com/creatorSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, I am thrilled to connect with Dr. Elizabeth Yurth. Dr. Yurth is double board-certified, as a physician in physical medicine and rehabilitation in addition to anti-aging and regenerative medicine. With over 30 years of clinical experience, Dr. Yurth continues to lead the way in orthopedics, cellular and regenerative medicine, and the future of aging. In our conversation, we explore immunosenescence and its implications for longevity. We discuss the off-label utilization of medications, including low-dose naltrexone, rapamycin, and GLP-1s, and examine other types of peptides, growth hormone secretagogues, and thymic peptides. We speak about hormones and anabolics, highlighting the benefits of anabolics for the bone health of those with osteopenia and osteoporosis. Dr. Yurth also shares her favorite supplements and outlines the key elements for optimal brain health. This episode is the first of a series of conversations with Dr. Yurth. She will join us again to dive into cardiovascular disease and explore powerful ways to support healthy aging at the cellular level. IN THIS EPISODE, YOU WILL LEARN: Why the thymus gland shrinks with age and what that means for immunity How thymic peptides support immune health, healing, and recovery The role thymosin alpha-1 plays in modulating the immune system Why thymosin beta-4 must be cycled for safe healing support How IGF (Insulin-like Growth Factor) decline impacts muscles, joints, and the brain with aging How growth hormone secretagogues can safely raise IGF How BPC-157 (a gastric peptide) aids gut repair, musculoskeletal healing, and brain protection Why mitochondrial peptides matter for energy, recovery, and repair How anabolics support bone strength and recovery How creatine and choline support the brain and muscles Bio: Elizabeth Yurth, MD, ABPMR, ABAARM, FAARM, FAARFM, FSSRP, is Co-Founder and Chief Medical Officer of Boulder Longevity Institute, where she has been providing Tomorrow's Medicine Today to her clients since 2006.  Dr. Yurth obtained her Medical Degree from the University of Southern California Keck School of Medicine, completed her residency at the University of California – Irvine, and her Fellowship in Sports and Spine Medicine from Stanford-affiliated Sports Orthopedics and Rehabilitation (SOAR) in Palo Alto, CA., along with her 30 years as a practicing orthopedist specializing in sports and spine medicine.  Dr. Yurth has made it her mission to learn and share the latest scientific research on how to truly heal the body at the cellular level. She is Fellowship trained in Anti-Aging, Regenerative, and Cellular Medicine. She has completed +500 hours of CME training focused on Longevity, Nutrition, Epigenetics, Bioidentical Hormone Replacement Therapy, Regenerative Peptide Treatments, and Regenerative Orthopedic Procedures.  Dr. Yurth continues to serve as a thought leader in Cellular Medicine, speaking at longevity events across the world and teaching others through her position as a founding faculty member for Seeds Scientific Research and Performance Institute (SSRP), which leads the way in connecting the latest research to clinical practice. Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Elizabeth Yurth On her website Dr. Yurth on Facebook The Boulder Longevity Institute on Facebook Dr. Yurth on Instagram The Boulder Longevity Institute on Instagram

Michael Hein, MS, MD, MHCM, Associate Certified Coach (ACC), believes that when healthcare leaders don't fully understand complexity, it leads to burnout, turnover, and poor patient care—issues he considers preventable forms of human suffering. Healthcare is more complex than ever, and traditional top-down methods often exacerbate these challenges. Success today requires leaders who adapt, absorb uncertainty, and react quickly. For many, this means embracing new leadership mindsets. With over thirty years of experience in healthcare, Michael is Senior Vice President and an executive coach at MEDI Leadership, the top healthcare coaching firm in the US. Drawing from clinical and executive roles, he helps leaders make the mindset shifts needed for success in complexity.Previously, Michael was CEO of a nonmerger hospital network and Chief Medical Officer at Catholic Health Initiatives. He led transformations at the Veterans Health Administration and cofounded KPI Ninja, a healthcare data company.Michael holds degrees from the University of South Dakota, Harvard's T.H. Chan School of Public Health, and St. Cloud State University. He is a certified executive coach through the International Coaching Federation, trained at the Hudson Institute of Coaching. His experience bridges frontline care and strategic leadership, coaching leaders to drive sustainable change in complex organizations.His book, Shifting Toward Unorthodoxy: Ten Unconventional Mindsets that Help Healthcare Leaders Succeed in a Complex World, encourages a shift from outdated leadership mindsets to adaptive ones. A lifelong athlete, Michael enjoys cycling and swimming.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

“Probably the most exciting thing I've seen in gene therapy over the last ten years is we now have a lot of tools for selective delivery, which will hopefully make treatments more safe and a lot more successful,” says Dr. Jessica Duis, a geneticist and pediatrician focused on the management of individuals with complex, rare disorders. Dr. Duis, who has worked on several gene therapies that are now approved or progressing through the accelerated approval pathway, is currently VP of Clinical Development at GondolaBio, a clinical-stage biopharmaceutical company focused on developing therapeutics for genetic diseases. As you'll learn in this Year of the Zebra episode with host Lindsey Smith, Dr. Duis is encouraged by other recent advances in genetic technology as well, and thinks momentum will grow as breakthrough treatments emerge. “I think we're hopefully going to continue to see companies that are working in rare disease be more successful and really drive how regulators think about making decisions in terms of bringing treatments to patients. I think we're at the tip of the iceberg in terms of the future of truly transformational therapies.”  This wide ranging conversation also explores Dr. Duis' team approach to patient care, her work on clinical endpoints, the importance of patient communities, and her book series, Rare Siblings Stories.Mentioned in this episode:GondolaBioRareDiseaseDocElsevier Healthcare Hub on Rare DiseasesRare Sibling Stories If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Ready to turn procrastination into productivity and make to-do lists work for you? Dr. Bradley Block and Dr. Russell Ramsay continue their discussion on time management for physicians. In part two, Dr. Ramsay explores forgiving procrastination through normalization, identifying progressivity (productive avoidance), and breaking tasks into small, actionable steps. He shares tips on using daily planners, keeping to-do lists manageable (2-5 items), and incorporating self-compassion to sustain motivation. While rooted in ADHD strategies, these insights help anyone in high-demand fields like medicine avoid overcommitment and build momentum. Tune in for practical advice on planners, task breakdown, and iterating for success—perfect for shifting work-life balance.Three Actionable Takeaway:Forgive and Normalize Procrastination – Recognize that relapse is 100%, and focus on understanding why it happens (e.g., lack of planning or overcommitment). Dr. Ramsay advises reframing through normalization and self-compassion: acknowledge slip-ups, identify specific causes, and get back on track without self-judgment to minimize future occurrences.Avoid Progressivity with Task Prioritization – Identify when you're doing lower-priority tasks (e.g., organizing files instead of charting) as avoidance. Dr. Ramsay suggests making priority tasks more appealing by focusing on hands-on starts, clear endpoints, and small steps—like mowing the lawn before taxes—to build momentum and prevent productive procrastination.Optimize To-Do Lists and Planners – Keep lists short (2-5 bite-sized items) and specific (e.g., "run errand" vs. vague goals). Dr. Ramsay recommends using planners for time-blocking, sequencing tasks logically, and iterating if needed; if a task lingers, break it down further into initial steps like "get to workstation" for sustained progress.About the Show:Succeed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Russell Ramsay is a psychologist specializing in the assessment and psychosocial treatment of adult ADHD. With international lectures and over six books, including CBT for Adult ADHD and The Adult ADHD Toolkit, he advises on behavioral strategies for efficiency and well-being. Formerly at the University of Pennsylvania Perelman School of Medicine, he focuses on helping professionals, including physicians, manage procrastination and perfectionism. LinkedIn: https://www.linkedin.com/in/russell-ramsay-a8bbb310Website: https://www.cbt4adhd.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.